Cargando…
Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
BACKGROUND: Esophageal adenocarcinoma is a lethal disease. For locally advanced patients, neoadjuvant chemoradiotherapy followed by surgery is the standard of care. Risk stratification relies heavily on clinicopathologic features, particularly pathologic response, which is inadequate, therefore esta...
Autores principales: | Matani, Hirsch, Sahu, Divya, Paskewicz, Michael, Gorbunova, Anastasia, Omstead, Ashten N., Wegner, Rodney, Finley, Gene G., Jobe, Blair A., Kelly, Ronan J., Zaidi, Ali H., Goel, Ajay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664643/ https://www.ncbi.nlm.nih.gov/pubmed/36376989 http://dx.doi.org/10.1186/s40364-022-00429-6 |
Ejemplares similares
-
Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model
por: Zaidi, Ali H., et al.
Publicado: (2021) -
Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1
por: Tayshetye, Pritam, et al.
Publicado: (2022) -
Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma
por: Babar, Laila, et al.
Publicado: (2019) -
Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma
por: Matsui, Daisuke, et al.
Publicado: (2016) -
CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
por: Kosovec, Juliann E., et al.
Publicado: (2017)